x

Like our Facebook Page

   
Early Times Newspaper Jammu, Leading Newspaper Jammu
 
Breaking News :   Ganesh Chaturthi Festival | Trouble increased due to changed Eating Habits | Mighty India is capable of taking her rightful place in the world of sports. | Trail of Destruction | 4 more bodies recovered, death toll reaches 45; rescue work underway | Schools to remain closed till Aug 31 Classrooms, campuses inundated | Doda remains cut off | Will sit with officers to understand mitigation measures taken after 2014 deluge: CM Omar | Railways run special train for stranded passengers | Jammu-Srinagar National Highway shut | ‘Traffic on Mughal Road allowed only till 4:30 PM’ | RSS Chief reaffirms unity, calls for stronger India | Short work season poses major challenge in Chasoti rehabilitation | Infiltration bid foiled in Gurez, 2 terrorists killed: Army | Terrorist involved in grenade attack held | CB arrests cashier for misappropriation of funds | Terrorists targeted Baisaran for high tourist footfall: NIA | Army soldier dies in Kupwara | All Assembly committee meetings suspended | Satish Kumar gets 1-year extension | JMC Commissioner inspects flood-affected areas assures swift relief and clean-up measures | PM Modi's PMJDY revolutionizes financial inclusion: Rekha Mahajan | Abhay Bakaya visits flood-affected ward 71, calls for immediate relief and road restoration | S Manjit Singh visit Gujjar Nagar, Jogi Gate | Javed Rana reviews water supply restoration measures in flood-affected areas of Jammu city | CCI president expresses deep sorrow over unfortuante cloudburst | Fix responsibility in Mata Vaishno Devi tragedy | LG Ladakh, First Lady pay homage to Kargil War Heroes at Drass War Memorial | Back Issues  
 
news details
Phase-3 clinical trial enrolment for India’s first Dengue vaccine to be completed by October: ICMR
7/13/2025 9:36:08 PM
NEW DELHI, July 13:

Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed dengue vaccine, DengiAll, is likely to be completed by October across 20 centres in India, according to ICMR scientists.
So far, 8,000 participants in various centres at Pune, Chennai, Kolkata, Delhi and Bhubaneswar among others have received either the vaccine or a placebo as part of the trial sponsored by the Indian Council of Medical Research (ICMR) and Panacea Biotec.
The trial is co-led by ICMR-National Institute of Translational Virology and AIDS research in Pune, National Institute of Epidemiology (NIE), Chennai and National Institute of Virology, Pune.
Currently, there is no antiviral treatment or licensed vaccine against dengue in India.
The results of the Phase-1/2 trial has shown no safety concerns for the one-shot vaccine, NIE Director Dr Manoj Murhekar said.
“The participants enrolled in the Phase- III trial will be followed up for two-years. This trial will evaluate the efficacy of this tetravalent dengue vaccine,” Dr Murhekar said.
The multi-centre, double-blind, randomised, placebo-controlled phase-III trial was launched in August last year to evaluate the jab’s efficacy, safety and, long-term immunogenicity.
The first participant in this trial was vaccinated at the Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS), Rohtak last year.
The development of an effective vaccine is complex due to the need to achieve good efficacy for all four serotypes. The dengue virus has four serotypes, 1-4, with low cross-protection a
About 10,500 participants have enrolled in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed dengue vaccine.
DengiAll, is likely to be completed by October across 20 centres in India, according to ICMR scientists.
So far, 8,000 participants in various centres at Pune, Chennai, Kolkata, Delhi and Bhubaneswar among others have received either the vaccine or a placebo.
The trial is co-led by ICMR-National Institute of Translational Virology and AIDS research in Pune, National Institute of Epidemiology (NIE), Chennai and National Institute of Virology, Pune.
ainst each other, meaning individuals can experience repeated infections, Dr Murhekar said.
In India, all four serotypes of dengue virus are known to circulate or co-circulate in many regions.
The Union Health Ministry in a statement earlier had said that the tetravalent dengue vaccine strain (TV003/TV005), originally developed by the National Institutes of Health (NIH), USA, has shown promising results in clinical trials in Brazil.
Panacea Biotec, one of three Indian companies to receive the strain, is at the most advanced stage of development. The company has worked extensively on these strains to develop a full-fledged vaccine formulation and holds a process patent for this work.
Dengue is a major public health concern in India, ranking among the top 30 countries with the highest incidence of the disease.
The global incidence of dengue has been steadily increasing over the past two decades, with more than 129 countries reporting dengue viral disease by the end of 2023, according to the World Health Organisation (WHO).
In India, approximately 75-80 per cent of infections are asymptomatic, yet these individuals can still transmit the infection through the bite of Aedes mosquitoes.
Among the 20-25 per cent of cases where symptoms are clinically apparent, children are at a significantly higher risk of hospitalisation and mortality. In adults, the disease can escalate into severe conditions like dengue hemorrhagic fever and dengue shock syndrome.
According to the government data, around 12,043 dengue cases were reported till March this year. In 2024, 2.3 lakh cases and 297 deaths had been recorded. (PTI)
  Share This News with Your Friends on Social Network  
  Comment on this Story  
 
 
 
Early Times Android App
STOCK UPDATE
  
BSE Sensex
NSE Nifty
 
CRICKET UPDATE
 
 
 
 
 
 
 
 
   
Home About Us Top Stories Local News National News Sports News Opinion Editorial ET Cetra Advertise with Us ET E-paper
 
 
J&K RELATED WEBSITES
J&K Govt. Official website
Jammu Kashmir Tourism
JKTDC
Mata Vaishnodevi Shrine Board
Shri Amarnath Ji Shrine Board
Shri Shiv Khori Shrine Board
UTILITY
Train Enquiry
IRCTC
Matavaishnodevi
BSNL
Jammu Kashmir Bank
State Bank of India
PUBLIC INTEREST
Passport Department
Income Tax Department
JK CAMPA
JK GAD
IT Education
Web Site Design Services
EDUCATION
Jammu University
Jammu University Results
JKBOSE
Kashmir University
IGNOU Jammu Center
SMVDU